AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32285126 — intervention group
Group type: COMPARATOR
Intervention: IV decitabine (20 mg/m2)
Number of subjects: 80
Study 35321792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preformed titanium plates and optimized 3D digital surgical guide plates (Group A)
Number of subjects: 26
Study 35321792 — intervention group
Group type: COMPARATOR
Intervention: Preformed titanium plates only (Group B)
Number of subjects: 26
Study 35321792 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Group C)
Number of subjects: 26
Study 35321792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (optimized 3D digital surgical guide plates)
Number of subjects: 26
Study 34540641 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (RG) with infusion of Ringer’s lactate at a rate of 3 mL/kg/h
Number of subjects: 80
Study 34540641 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management (CG) with Ringer’s lactate at conventional calculated doses
Number of subjects: 80
Study 34540641 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (RG)
Number of subjects: 80
Study 34540641 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management (CG)
Number of subjects: 80
Study 32636099 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethroplasty
Number of subjects: 222
Study 32636099 — intervention group
Group type: COMPARATOR
Intervention: Urethrotomy
Number of subjects: 222
Study 35157498 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiracism intervention (real-time warning system, race-specific feedback, patient navigation)
Number of subjects: 2363
Study 35157498 — intervention group
Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 2363
Study 35157498 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control group
Number of subjects: 2363
Study 35157498 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiracism intervention
Number of subjects: 2363
Study 33107596 — intervention group
Group type: EXPERIMENTAL
Intervention: AgP+CS/EMD
Number of subjects: 60
Study 33107596 — intervention group
Group type: COMPARATOR
Intervention: AgP+CS
Number of subjects: 60
Study 33107596 — intervention group
Group type: EXPERIMENTAL
Intervention: CP+CS/EMD
Number of subjects: 60
Study 33107596 — intervention group
Group type: COMPARATOR
Intervention: All groups (AgP+CS, AgP+CS/EMD, CP+CS/EMD)
Number of subjects: 60
Study 35057774 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Lessons (HL)
Number of subjects: 0
Study 35057774 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 32416055 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride test formulation (150 mg)
Number of subjects: 0
Study 32416055 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib hydrochloride reference formulation (150 mg)
Number of subjects: 0
Study 34153269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 3725
Study 34153269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3725
Study 32359104 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene 20 mg
Number of subjects: 0
Study 35309166 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-modified training (CMT)
Number of subjects: 213
Study 35309166 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 213
Study 35309166 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated match-play (SMP)
Number of subjects: 213
Study 34027702 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary alternative medicine (CAM)
Number of subjects: 57
Study 34027702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier only)
Number of subjects: 57
Study 35633810 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOSA (Eating and Control Styles Axis) used during mentalisation-based psychotherapy
Number of subjects: 94
Study 35633810 — intervention group
Group type: COMPARATOR
Intervention: Mentalisation-based psychotherapy (control group)
Number of subjects: 94
Study 35633810 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOSA usage
Number of subjects: 94
Study 35633810 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with EDE-Q score in the intervention group
Number of subjects: 94
Study 33438313 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine cleaning
Number of subjects: 648
Study 33438313 — intervention group
Group type: COMPARATOR
Intervention: No cleaning
Number of subjects: 648
Study 35314794 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 62
Study 36376887 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 100 mg/kg/day
Number of subjects: 11
Study 36376887 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 250 mg/kg/day
Number of subjects: 11
Study 32251641 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg P2-VP8 vaccine
Number of subjects: 617
Study 32251641 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg P2-VP8 vaccine
Number of subjects: 617
Study 32251641 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg P2-VP8 vaccine
Number of subjects: 617
Study 32251641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 35829751 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak heart rate prediction equation based on resting HR, presence of diabetes, physical dysfunction (gait speed < 1.0 m/s), and hypoalbuminemia (< 3.5 g/dL)
Number of subjects: 126
Study 35829751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise based on estimated peak HR < 85%
Number of subjects: 126
Study 35829751 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured peak HR values
Number of subjects: 126
Study 35829751 — intervention group
Group type: EXPERIMENTAL
Intervention: HR at anaerobic threshold (AT)
Number of subjects: 126
Study 32097165 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective anterior resection surgery
Number of subjects: 132
Study 35351443 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital person‐centered care training intervention with virtual coaching
Number of subjects: 175
Study 35351443 — intervention group
Group type: COMPARATOR
Intervention: Digital training program alone
Number of subjects: 175
Study 33705168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Coping Cat)
Number of subjects: 488
Study 33705168 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 488
Study 33705168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cognitive Behavioral Therapy and Medication
Number of subjects: 488
Study 33705168 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study 32609171 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Mean Matching (PMM)
Number of subjects: 0
Study 32609171 — intervention group
Group type: COMPARATOR
Intervention: Hot deck
Number of subjects: 0
Study 36087316 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 139
Study 32956756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks for 32 weeks)
Number of subjects: 108
Study 32956756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 4 weeks for 32 weeks)
Number of subjects: 108
Study 32956756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 108
Study 32956756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 36416598 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) in self-etch mode (SE)
Number of subjects: 96
Study 36416598 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Universal (OPU) in self-etch mode (SE)
Number of subjects: 96
Study 36416598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick (CBQ) in self-etch mode (SE)
Number of subjects: 96
Study 36416598 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesives in etch-and-rinse mode (ER)
Number of subjects: 96
Study 33999939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 15 min
Number of subjects: 16
Study 33999939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 30 min
Number of subjects: 16
Study 33999939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 45 min
Number of subjects: 16
Study 33999939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 60 min
Number of subjects: 16
Study 33999939 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16
Study 35303390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 75
Study 33887652 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct gaze directed at the observer
Number of subjects: 0
Study 33887652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stimuli where gaze appeared to move toward the participant
Number of subjects: 0
Study 33887652 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli showing a full face, eye region, inverted faces, and high-contrast eye-like stimuli
Number of subjects: 0
Study 33887652 — intervention group
Group type: COMPARATOR
Intervention: Static pictures of full faces and dynamic nonfigurative stimuli
Number of subjects: 0
Study 34508582 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 594
Study 34508582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 32506504 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM‐ICE (zero-fluoroscopy)
Number of subjects: 57
Study 32506504 — intervention group
Group type: COMPARATOR
Intervention: F‐ICE (fluoroscopy)
Number of subjects: 57
Study 36428016 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, humidified, high-flow nasal cannula oxygen postextubation
Number of subjects: 0
Study 36428016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (treatment at the discretion of the treating provider)
Number of subjects: 0
Study 34463538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led interventions
Number of subjects: 0
Study 34463538 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35760117 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Number of subjects: 12
Study 32037737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedar fragrance (aroma extracts from cedar) added to disinfecting ethanol, administered for 8 weeks.
Number of subjects: 36
Study 32037737 — intervention group
Group type: COMPARATOR
Intervention: Ethanol without added aroma extracts (control group), administered for 8 weeks.
Number of subjects: 36
Study 34982798 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in HCC patients
Number of subjects: 200
Study 34982798 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in LC patients
Number of subjects: 200
Study 34982798 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in CH patients
Number of subjects: 200
Study 34982798 — intervention group
Group type: EXPERIMENTAL
Intervention: H94 deletion in the Enh‐II region
Number of subjects: 200
Study 34982798 — intervention group
Group type: EXPERIMENTAL
Intervention: Notable mutations E109A/Y, A110S/K, Y111D/E, F112L
Number of subjects: 200
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bile acids
Number of subjects: 136
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal bile acids
Number of subjects: 136
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum short chain fatty acids
Number of subjects: 136
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal short chain fatty acids
Number of subjects: 136
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids and short chain fatty acids
Number of subjects: 136
Study 34376486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids
Number of subjects: 136
Study 35427929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task group (DT) with an additional auditory 1-back task
Number of subjects: 80
Study 35427929 — intervention group
Group type: COMPARATOR
Intervention: Single task group (ST)
Number of subjects: 80
Study 35427929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task group with visual feedback delay (DTDEL)
Number of subjects: 80
Study 35427929 — intervention group
Group type: COMPARATOR
Intervention: Single task group with visual feedback delay (STDEL)
Number of subjects: 80
Study 35427929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task group without visual feedback delay (DTNoDEL)
Number of subjects: 80
Study 35427929 — intervention group
Group type: COMPARATOR
Intervention: Single task group without visual feedback delay (STNoDEL)
Number of subjects: 80
Study 32772079 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based ART
Number of subjects: 170
Study 35771552 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led intervention (usual care with 6-month CHW-led intervention)
Number of subjects: 128
Study 35771552 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led intervention
Number of subjects: 128
Study 35771552 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 128
Study 34204042 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural extract of Sclerocarya birrea, 100 mg daily for 90 days
Number of subjects: 67
Study 34204042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 35451391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/(kg·h) of dexmedetomidine
Number of subjects: 60
Study 35451391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 μg/(kg·h) of dexmedetomidine
Number of subjects: 60
Study 35451391 — intervention group
Group type: COMPARATOR
Intervention: 0.4 μg/(kg·h) of dexmedetomidine
Number of subjects: 60
Study 35917052 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET) for 4 months before surgery
Number of subjects: 410
Study 35917052 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 410
Study 35568822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal dexmedetomidine (1 µg/kg) combined with 0.8% ropivacaine (40 mg)
Number of subjects: 200
Study 35568822 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control Group S)
Number of subjects: 200
Study 35568822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal dexmedetomidine (1 µg/kg)
Number of subjects: 200
Study 35568822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% ropivacaine (40 mg)
Number of subjects: 200
Study 33546947 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of netrin-1
Number of subjects: 3065
Study 33546947 — intervention group
Group type: COMPARATOR
Intervention: Normal TC levels
Number of subjects: 3065
Study 33546947 — intervention group
Group type: EXPERIMENTAL
Intervention: Netrin-1 added to conventional risk factors
Number of subjects: 3065
Study 36469298 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg/day for 28 days
Number of subjects: 120
Study 36469298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) through naso-duodenal tube, daily for seven days
Number of subjects: 120
Study 33169227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective epilepsy surgery
Number of subjects: 3
Study 33169227 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 3
Study 32954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (specific drugs not mentioned) for VVS patients
Number of subjects: 459
Study 32954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifascicular block patients
Number of subjects: 459
Study 32954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥4 faints in the prior year
Number of subjects: 459
Study 32954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of syncope patients
Number of subjects: 459
Study 34285005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily) + Exenatide QW (2 mg once weekly)
Number of subjects: 110
Study 34285005 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 110
Study 34285005 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo tablet and sham injection)
Number of subjects: 110
Study 34285005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Exenatide QW
Number of subjects: 110
Study 32135610 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C lesion group (n=614)
Number of subjects: 1255
Study 32135610 — intervention group
Group type: COMPARATOR
Intervention: Type A/B1 lesion group (n=184)
Number of subjects: 1255
Study 32135610 — intervention group
Group type: COMPARATOR
Intervention: Type B2 lesion group (n=457)
Number of subjects: 1255
Study 36050633 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed child chest compression
Number of subjects: 0
Study 36050633 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed child chest compression
Number of subjects: 0
Study 36050633 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32958014 — intervention group
Group type: COMPARATOR
Intervention: nab-P 40 µmol/l
Number of subjects: 0
Study 32958014 — intervention group
Group type: COMPARATOR
Intervention: AP 50 µmol/l
Number of subjects: 0
Study 32958014 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 5 µmol/l + AP 10 µmol/l
Number of subjects: 0
Study 32958014 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 20 mg/kg + AP 150 mg/kg
Number of subjects: 0
Study 32958014 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 18 mg/kg + AP 150 mg/kg
Number of subjects: 0
Study 32958014 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 16 mg/kg + AP 150 mg/kg
Number of subjects: 0
Study 32958014 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of nab-P
Number of subjects: 0
Study 35505441 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mg/mL EGCG solution
Number of subjects: 15
Study 35505441 — intervention group
Group type: COMPARATOR
Intervention: Routine periodontal therapy (Control)
Number of subjects: 15
Study 33306989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine (two standard doses)
Number of subjects: 23648
Study 33306989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine (low dose followed by standard dose)
Number of subjects: 23648
Study 33306989 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of ChAdOx1 nCoV‐19 vaccine
Number of subjects: 23648
Study 33306989 — intervention group
Group type: COMPARATOR
Intervention: Control group (meningococcal group A, C, W, and Y conjugate vaccine or saline)
Number of subjects: 23648
Study 33306989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine and control group
Number of subjects: 23648
Study 35877150 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 30
Study 35877150 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 30
Study 33136088 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated trunk extensor (TE) muscle endurance
Number of subjects: 30
Study 32967619 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs) aimed at initiating and optimizing advance care planning (ACP)
Number of subjects: 0
Study 32967619 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs
Number of subjects: 0
Study 36237892 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based teaching material
Number of subjects: 69
Study 36237892 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based teaching material
Number of subjects: 69
Study 36237892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 33780486 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital early literacy intervention
Number of subjects: 695
Study 33780486 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 695
Study 33780486 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard measures (various definitions)
Number of subjects: 695
Study 33780486 — intervention group
Group type: EXPERIMENTAL
Intervention: Most precise definition of the gold standard level
Number of subjects: 695
Study 32788190 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine, Gardasil 9
Number of subjects: 0
Study 32788190 — intervention group
Group type: COMPARATOR
Intervention: Placebo hepatitis A vaccine, Avaxim
Number of subjects: 0
Study 35906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy-protein (BEP) supplement and iron-folic acid (IFA) tablet
Number of subjects: 0
Study 35906874 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) tablet
Number of subjects: 0
Study 33779698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (20 mg once daily)
Number of subjects: 1133
Study 33779698 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide (14 mg once daily)
Number of subjects: 1133
Study 32912597 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN)
Number of subjects: 2599
Study 32912597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2599
Study 32912597 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN) lower-dose subgroup
Number of subjects: 2599
Study 32912597 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN) higher-dose subgroup
Number of subjects: 2599
Study 35325161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric quinine hydrochloride (600 mg QHCl)
Number of subjects: 28
Study 35325161 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal quinine hydrochloride (600 mg QHCl)
Number of subjects: 28